Alejandro Alagón Cano
Mexican medical doctor, researcher and academic
You can help expand this article with text translated from the corresponding article in Spanish. (February 2023) Click [show] for important translation instructions.
- Machine translation, like DeepL or Google Translate, is a useful starting point for translations, but translators must revise errors as necessary and confirm that the translation is accurate, rather than simply copy-pasting machine-translated text into the English Wikipedia.
- Do not translate text that appears unreliable or low-quality. If possible, verify the text with references provided in the foreign-language article.
- You must provide copyright attribution in the edit summary accompanying your translation by providing an interlanguage link to the source of your translation. A model attribution edit summary is
Content in this edit is translated from the existing Spanish Wikipedia article at [[:es:Alejandro Alagón Cano]]; see its history for attribution. - You may also add the template
{{Translated|es|Alejandro Alagón Cano}}to the talk page. - For more guidance, see Wikipedia:Translation.
Alejandro Alagón Cano | |
|---|---|
 Alejandro in his office, photo captured (2016) | |
| Education | National Autonomous University of Mexico |
| Occupation | Physician |
| Employer | National Autonomous University of Mexico |
| Awards | National Prize for Arts and Sciences Mexico (2005) |
Alejandro Alagón Cano is a Mexican doctor, researcher, professor and academic. He was an active researcher during the development process of the scorpion antivenom Alacramyn and the pit viper antivenom Antivipmyn, both manufactured by Instituto Bioclon in Mexico. These products were later approved for commercial distribution by the United States Food and Drug Administration (FDA) in 2011 and 2015 and are marketed under the names Anascorp[1] and Anavip,[2] respectively.
Education
Alagón completed his undergraduate degree at the Faculty of Medicine of the National Autonomous University of Mexico (UNAM), later he completed a master's degree and a doctorate in biomedical research, at the same institution. He did postdoctoral studies at Rockefeller University in New York.
Career
Alagón joined the faculty and researchers at the Institute of Biotechnology at his alma mater where he has been coordinator of master's and doctoral programs in biochemical sciences and academic secretary at the Center for Research on Genetic Engineering and Biotechnology.[citation needed] He has been instrumental in the development of antivenoms used throughout the Americas and Africa.[3] In the USA he is known for his work on Anascorp, the first scorpion antivenom approved since the establishment of the modern FDA.[4] He is currently a Professor Emeritus at the Institute of Biotechnology-UNAM.[5]
Awards and distinctions
- National University Award (PUN) in the area of Innovation and Technology granted by the National Autonomous University of Mexico in 2004. [6]
- National Prize for Arts and Sciences (Mexico) award granted by the Secretariat of Public Education (Mexico) in 2005.[7]
- Premio Luis Elizondo award granted by the Monterrey Institute of Technology and Higher Education in 2013 [8]
References
- ^ "| Home". Anascorp®. Retrieved 2023-05-22.
- ^ "ANAVIP Home". ANAVIP® [crotalidae immune F(ab’)₂ (equine)]. Retrieved 2023-05-23.
- ^ "How Mexico revolutionized the science of antivenom". Animals. 2022-04-18. Archived from the original on April 18, 2022. Retrieved 2023-05-23.
- ^ "First scorpion antivenom approved by FDA". EurekAlert!. Retrieved 2023-05-23.
- ^ www.ibt.unam.mx. "Dr. Alejandro Alagón Cano". Instituto de Biotecnología - UNAM. Retrieved 2023-05-23.
- ^ "Alejandro Alagón Cano". www.cua.uam.mx (in Spanish). Retrieved 2023-01-27.
- ^ "Premio Nacional de Ciencias y Arte" (PDF).
- ^ "Red de Portales News Detail Page". www.universia.net. Retrieved 2023-01-27.
